1-4 of 4
Bérengère de Moucheron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Marie Michot, Franck Morschhauser, Silvia Ferrari, Judit Mészáros Jørgensen, Loretta Nastoupil, Emmanuel Bachy, Michael Pourdehnad, Akshay Sudhindra, Alev Akyol, Bérengère de Moucheron, Soraya Carrancio, Jessica Voetsch, Xirong Zheng, Julio C. Chavez
Journal: Blood
Blood (2024) 144 (Supplement 1): 869.
https://doi.org/10.1182/blood-2024-203163
Published: 2024
Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot
Journal: Blood
Blood (2024) 144 (Supplement 1): 3018.
https://doi.org/10.1182/blood-2024-203131
Published: 2024
Journal Articles

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Soraya Carrancio, Jessica Voetsch, Alberto Risueño, Carla Guarinos, Siddhesh Kulkarni, Mandeep Takhar, Matthew E. Stokes, Bérengère de Moucheron, Laura Furman, Julio C. Chavez, Jean-Marie Michot, Loretta Nastoupil, Daniel W. Pierce, Danielle Greenawalt, Michael Pourdehnad
Journal: Blood
Blood (2024) 144 (Supplement 1): 3104.
https://doi.org/10.1182/blood-2024-203139
Published: 2024
Journal Articles

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Julio C. Chavez, Loretta J. Nastoupil, Franck Morschhauser, Guillaume Cartron, Judit Mészáros Joergensen, Emmanuel Bachy, Pierre Bories, Victoria Campbell, Bijou Fontanet, Poliana P. Patah, Bérengère de Moucheron, Soraya Carrancio, Xirong Zheng, Chaoqun Mei, Michael Pourdehnad, Jean-Marie Michot
Journal: Blood
Blood (2023) 142 (Supplement 1): 4496.
https://doi.org/10.1182/blood-2023-188771
Published: 2023